Ropes & Gray Represents TESARO in its $5.1 Billion Acquisition by GSK

Ropes & Gray represented TESARO, an oncology focused biopharmaceutical company, in its agreement to be acquired by GSK plc, for an aggregate cash consideration of approximately $5.1 billion or $75 per share. TESARO is a commercial-stage biopharmaceutical company, with a major marketed product, Zejula (niraparib), an oral poly ADP ribose polymerase inhibitor currently approved for use in ovarian cancer. The proposed transaction significantly strengthens GSK’s pharmaceutical business, accelerating the build of GSK’s pipeline and commercial capability in oncology. The transaction is expected to be completed in the first quarter of 2019.

The Ropes & Gray team representing TESARO includes securities & public companies partners Christopher Comeau and Paul Kinsella, benefits partner Megan Bisk, antitrust partner Michael McFalls, tax partner David Saltzman, IP transactions partner David McIntosh, life sciences partner Al Cacozza, health care partner Eve Brunts and litigation & enforcement partners Peter Welsh and Ama Adams.